Details for Patent: 8,927,592

Which drugs does patent 8,927,592 protect, and when does it expire?

Patent 8,927,592 protects JEVTANA KIT and is included in one NDA.

Protection for JEVTANA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-three patent family members in thirty-four countries.

Summary for Patent: 8,927,592

Title:	Antitumoral use of cabazitaxel
Abstract:	The invention relates to a compound of formula: ##STR00001## which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Inventor(s):	Gupta; Sunil (Chester Springs, PA)
Assignee:	Aventis Pharma SA (Antony, FR)
Application Number:	13/456,720
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,927,592
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,927,592

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023-001	Jun 17, 2010	AP	RX	Yes	Yes					Y

International Family Members for US Patent 8,927,592

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	078824
Australia	2010310986
Australia	2015200149